» Articles » PMID: 30742861

Delayed Creatine Supplementation Counteracts Reduction of GABAergic Function and Protects Against Seizures Susceptibility After Traumatic Brain Injury in Rats

Abstract

Traumatic brain injury (TBI) is a devastating disease frequently followed by behavioral disabilities including post-traumatic epilepsy (PTE). Although reasonable progress in understanding its pathophysiology has been made, treatment of PTE is still limited. Several studies have shown the neuroprotective effect of creatine in different models of brain pathology, but its effects on PTE is not elucidated. Thus, we decided to investigate the impact of delayed and chronic creatine supplementation on susceptibility to epileptic seizures evoked by pentylenetetrazol (PTZ) after TBI. Our experimental data revealed that 4 weeks of creatine supplementation (300 mg/kg, p.o.) initiated 1 week after fluid percussion injury (FPI) notably increased the latency to first myoclonic and tonic-clonic seizures, decreased the time spent in tonic-clonic seizure, seizure intensity, epileptiform discharges and spindle oscillations induced by a sub-convulsant dose of PTZ (35 mg/kg, i.p.). Interestingly, this protective effect persists for 1 week even when creatine supplementation is discontinued. The anticonvulsant effect of creatine was associated with its ability to reduce cell loss including the number of parvalbumin positive (PARV+) cells in CA3 region of the hippocampus. Furthermore, creatine supplementation also protected against the reduction of GAD67 levels, GAD activity and specific [H]flunitrazepam binding in the hippocampus. These findings showed that chronic creatine supplementation may play a neuroprotective role on brain excitability by controlling the GABAergic function after TBI, providing a possible new strategy for the treatment of PTE.

Citing Articles

The Pathophysiology of Traumatic Brain Injuries and the Rationale Behind Creatine Supplementation as a Potential Therapy: A Review.

Vietor F, Sticher K, Ashraf K Mo Med. 2025; 122(1):60-66.

PMID: 39958598 PMC: 11827660.


Creatine Activity as a Neuromodulator in the Central Nervous System.

Meftahi G, Hatef B, Pirzad Jahromi G Arch Razi Inst. 2024; 78(4):1169-1175.

PMID: 38226371 PMC: 10787915. DOI: 10.32592/ARI.2023.78.4.1169.


Suggestion of creatine as a new neurotransmitter by approaches ranging from chemical analysis and biochemistry to electrophysiology.

Bian X, Zhu J, Jia X, Liang W, Yu S, Li Z Elife. 2023; 12.

PMID: 38126335 PMC: 10735228. DOI: 10.7554/eLife.89317.


Potential role of creatine as an anticonvulsant agent: evidence from preclinical studies.

Alraddadi E, Khojah A, Alamri F, Kecheck H, Altaf W, Khouqeer Y Front Neurosci. 2023; 17:1201971.

PMID: 37456992 PMC: 10339234. DOI: 10.3389/fnins.2023.1201971.


Neuropharmacological insight into preventive intervention in posttraumatic epilepsy based on regulating glutamate homeostasis.

Gao Y, Liu N, Chen J, Zheng P, Niu J, Tang S CNS Neurosci Ther. 2023; 29(9):2430-2444.

PMID: 37309302 PMC: 10401093. DOI: 10.1111/cns.14294.